Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.37 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737247 | 0.81 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1PTGS2PTGS1POLB | |
| SCHEMBL2737234 | 0.79 | L3MBTL1 (0.59) | L3MBTL1PTGS2PTGS1POLBCYP19A1 | |
| SCHEMBL2737232 | 0.79 | L3MBTL1 (0.59) | L3MBTL1POLBCYP19A1EP300KAT2B | |
| SCHEMBL15503304 | 0.79 | L3MBTL1 (0.59) | L3MBTL1SLC22A12PTGS2PTGS1POLB | |
| SCHEMBL2737218 | 0.77 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SLC22A12PTGS2PTGS1 | |
| SCHEMBL2737226 | 0.77 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1PTGS2PTGS1CYP19A1 | |
| SCHEMBL1542958 | 0.77 | ALDH1A1 (0.53) | ALDH1A1SLC22A12PTGS2PTGS1CYP19A1 | |
| SCHEMBL13337358 | 0.75 | ALDH1A1 (0.51) | ALDH1A1SLC22A12PTGS2PTGS1 | |
| SCHEMBL30526897 | 0.75 | KMT2A (0.56) | L3MBTL1ALDH1A1SLC22A12 | |
| SCHEMBL2350815 | 0.75 | KMT2A (0.56) | L3MBTL1ALDH1A1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957275-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9238039-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8809330-B2 | Pyrazolo[1,5-A]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8486938-B2 | Pyrazolo[1,5-a]pyrimidines for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140154240-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20140072554-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20160130275-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | L3MBTL1 4437/4885ALDH1A1 1823/4885SLC22A12 2328/4885 |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | L3MBTL1 2667/4885ALDH1A1 1436/4885SLC22A12 3684/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | L3MBTL1 2667/4885ALDH1A1 1436/4885SLC22A12 3684/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | L3MBTL1 2667/4885ALDH1A1 1436/4885SLC22A12 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.